<p>Marex Group plc 在第二季度收購了 Arrowhead Pharmaceuticals, Inc.（NASDAQ:ARWR - 免費報告）的新股份，根據其最近向證券交易委員會提交的文件。該基金收購了 36,469 股生物技術公司的股票，價值約為 576,000 美元。</p>
<ul>
<li>想要在生物技術領域獲得多元化的收益嗎？查看 LABU</li>
</ul>
<p>其他一些對沖基金最近也調整了對該公司的持股。Virtus Advisers LLC 在第二季度購買了 Arrowhead Pharmaceuticals 的新股份，價值 34,000 美元。Nisa Investment Advisors LLC 在第二季度將其在 Arrowhead Pharmaceuticals 的持股增加了 75.9%。Nisa Investment Advisors LLC 現在擁有 3,032 股生物技術公司的股票，價值 48,000 美元，在此期間又收購了 1,308 股。大和證券集團在第二季度將其在 Arrowhead Pharmaceuticals 的持股增加了 883.3%。大和證券集團現在擁有 4,189 股生物技術公司的股票，價值 66,000 美元，在此期間又收購了 3,763 股。未來資產全球投資有限公司在第二季度將其在 Arrowhead Pharmaceuticals 的持股增加了 29.5%。未來資產全球投資有限公司現在擁有 5,335 股生物技術公司的股票，價值 84,000 美元，在上個季度又收購了 1,214 股。最後，Lazard Asset Management LLC 在第二季度購買了 Arrowhead Pharmaceuticals 的新股份，價值約為 91,000 美元。對沖基金和其他機構投資者持有該公司 62.61% 的股份。</p>
<h2>分析師評級調整</h2>
<p>一些研究分析師最近對該股票進行了評論。Piper Sandler 將 Arrowhead Pharmaceuticals 的目標價格從 45.00 美元提高至 70.00 美元，並在 11 月 19 日的研究報告中給予該公司 “增持” 評級。摩根士丹利將 Arrowhead Pharmaceuticals 的目標價格從 45.00 美元提高至 48.00 美元，並在 11 月 26 日的報告中給予該公司 “持平” 評級。加拿大皇家銀行將 Arrowhead Pharmaceuticals 的目標價格從 52.00 美元提高至 80.00 美元，並在週四的報告中給予該股票 “跑贏大盤” 評級。美國銀行將 Arrowhead Pharmaceuticals 的目標價格從 62.00 美元提高至 81.00 美元，並在 12 月 9 日的研究報告中給予該公司 “買入” 評級。最後，Chardan Capital 重申了 “買入” 評級，並在 12 月 1 日的研究報告中對 Arrowhead Pharmaceuticals 的目標價格設定為 60.00 美元。兩位分析師給予該股票 “強烈買入” 評級，五位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Arrowhead Pharmaceuticals 的平均評級為 “適度買入”，共識目標價格為 58.56 美元。</p>
<p><strong>查看我們對 Arrowhead Pharmaceuticals 的最新股票分析</strong></p>
<h2>Arrowhead Pharmaceuticals 股價下跌 1.0%</h2>
<p>Arrowhead Pharmaceuticals 的股票在週一開盤價為 70.09 美元。Arrowhead Pharmaceuticals, Inc. 的一年低點為 9.57 美元，一年高點為 72.36 美元。該公司的 50 日移動平均價格為 45.48 美元，200 日移動平均價格為 29.55 美元。該公司的債務與股本比率為 0.43，流動比率為 4.86，速動比率為 4.86。該公司的市值為 95.2 億美元，市盈率為 -876.02，貝塔值為 1.28。</p>
<h2>Arrowhead Pharmaceuticals 的內部活動</h2>
<p>在其他新聞中，董事 Michael S. Perry 於 12 月 5 日星期五出售了 16,250 股公司的股票。股票以平均價格 61.03 美元出售，總價值為 991,737.50 美元。出售完成後，該董事直接持有 115,240 股公司股票，價值約為 7,033,097.20 美元。此次交易使其持股減少了 12.36%。該出售在向證券交易委員會的文件中披露，可以通過此超鏈接訪問。此外，董事 Mauro Ferrari 於 11 月 28 日星期五出售了 8,750 股公司的股票。股票以平均價格 56.39 美元出售，總交易額為 493,412.50 美元。交易完成後，該董事持有 68,764 股公司股票，價值 3,877,601.96 美元。此次交易使其持股減少了 11.29%。該出售的披露信息可在 SEC 文件中找到。在過去的九十天裏，內部人士已出售價值 2,185,150 美元的 45,000 股公司股票。公司內部人士持有該公司 4.30% 的股份。</p>
<h2>關於 Arrowhead Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Arrowhead Pharmaceuticals, Inc. 在美國開發治療難治性疾病的藥物。該公司的產品管線包括 Plozasiran，目前正在進行 2b 期和一項 3 期臨牀試驗，以治療高甘油三酯血癥、混合性血脂異常和乳糜微粒血癥；Zodasiran 正在進行 2b 期臨牀試驗，以治療血脂異常和高甘油三酯血癥；ARO-PNPLA3 正在進行 1 期臨牀試驗，以治療非酒精性脂肪性肝炎患者；ARO-RAGE 正在進行 1/2a 期臨牀試驗，以治療炎症性肺部疾病；ARO-MUC5AC 正在進行 1/2a 期臨牀試驗，以治療粘液阻塞性肺病。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比 Arrowhead Pharmaceuticals 更好</li>
<li>投資者必須瞭解的場外（OTC）股票信息</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了遊戲</li>
<li>每股收益計算器：如何計算 EPS</li>
<li>3 只金融股票在 10 年期國債收益率上升時值得購買</li>
<li>如何從價值投資中獲利</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Arrowhead Pharmaceuticals 嗎？</h2>
<p>在你考慮 Arrowhead Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Arrowhead Pharmaceuticals 並不在名單上。</p>
<p>雖然 Arrowhead Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

箭頭制藥

<p>Marex Group plc 在第二季度收購了 36,469 股 Arrowhead Pharmaceuticals, Inc. 的股票，價值約為 576,000 美元。其他幾家對沖基金也調整了在該公司的持股。分析師對 Arrowhead Pharmaceuticals 給予了 “適度買入” 的評級，目標價共識為 58.56 美元。該股票開盤價為 70.09 美元，市值為 95.2 億美元。最近的內部交易涉及董事 Michael S. Perry 和 Mauro Ferrari 的股票出售</p>

<p>Marex Group plc acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 36,469 shares of the biotechnology company's stock, valued at approximately $576,000.</p>
<div class="lb-trans"><p>Marex Group plc 在第二季度收購了 Arrowhead Pharmaceuticals, Inc.（NASDAQ:ARWR - 免費報告）的新股份，根據其最近向證券交易委員會提交的文件。該基金收購了 36,469 股生物技術公司的股票，價值約為 576,000 美元。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技術領域獲得多元化的收益嗎？查看 LABU</li>
</ul>
</div><p>A number of other hedge funds also recently modified their holdings of the business. Virtus Advisers LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $34,000. Nisa Investment Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,308 shares during the period. Daiwa Securities Group Inc. boosted its position in Arrowhead Pharmaceuticals by 883.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after acquiring an additional 3,763 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Arrowhead Pharmaceuticals by 29.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after acquiring an additional 1,214 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $91,000. Hedge funds and other institutional investors own 62.61% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金最近也調整了對該公司的持股。Virtus Advisers LLC 在第二季度購買了 Arrowhead Pharmaceuticals 的新股份，價值 34,000 美元。Nisa Investment Advisors LLC 在第二季度將其在 Arrowhead Pharmaceuticals 的持股增加了 75.9%。Nisa Investment Advisors LLC 現在擁有 3,032 股生物技術公司的股票，價值 48,000 美元，在此期間又收購了 1,308 股。大和證券集團在第二季度將其在 Arrowhead Pharmaceuticals 的持股增加了 883.3%。大和證券集團現在擁有 4,189 股生物技術公司的股票，價值 66,000 美元，在此期間又收購了 3,763 股。未來資產全球投資有限公司在第二季度將其在 Arrowhead Pharmaceuticals 的持股增加了 29.5%。未來資產全球投資有限公司現在擁有 5,335 股生物技術公司的股票，價值 84,000 美元，在上個季度又收購了 1,214 股。最後，Lazard Asset Management LLC 在第二季度購買了 Arrowhead Pharmaceuticals 的新股份，價值約為 91,000 美元。對沖基金和其他機構投資者持有該公司 62.61% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of research analysts recently commented on the stock. Piper Sandler boosted their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, November 19th. Morgan Stanley boosted their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 26th. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $58.56.</p>
<div class="lb-trans"><p>一些研究分析師最近對該股票進行了評論。Piper Sandler 將 Arrowhead Pharmaceuticals 的目標價格從 45.00 美元提高至 70.00 美元，並在 11 月 19 日的研究報告中給予該公司 “增持” 評級。摩根士丹利將 Arrowhead Pharmaceuticals 的目標價格從 45.00 美元提高至 48.00 美元，並在 11 月 26 日的報告中給予該公司 “持平” 評級。加拿大皇家銀行將 Arrowhead Pharmaceuticals 的目標價格從 52.00 美元提高至 80.00 美元，並在週四的報告中給予該股票 “跑贏大盤” 評級。美國銀行將 Arrowhead Pharmaceuticals 的目標價格從 62.00 美元提高至 81.00 美元，並在 12 月 9 日的研究報告中給予該公司 “買入” 評級。最後，Chardan Capital 重申了 “買入” 評級，並在 12 月 1 日的研究報告中對 Arrowhead Pharmaceuticals 的目標價格設定為 60.00 美元。兩位分析師給予該股票 “強烈買入” 評級，五位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Arrowhead Pharmaceuticals 的平均評級為 “適度買入”，共識目標價格為 58.56 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Arrowhead Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Arrowhead Pharmaceuticals Trading Down 1.0%</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 股價下跌 1.0%</h2>
</div><p>Arrowhead Pharmaceuticals stock opened at $70.09 on Monday. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $72.36. The company's fifty day moving average price is $45.48 and its two-hundred day moving average price is $29.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of -876.02 and a beta of 1.28.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals 的股票在週一開盤價為 70.09 美元。Arrowhead Pharmaceuticals, Inc. 的一年低點為 9.57 美元，一年高點為 72.36 美元。該公司的 50 日移動平均價格為 45.48 美元，200 日移動平均價格為 29.55 美元。該公司的債務與股本比率為 0.43，流動比率為 4.86，速動比率為 4.86。該公司的市值為 95.2 億美元，市盈率為 -876.02，貝塔值為 1.28。</p>
</div><h2>Insider Activity at Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 的內部活動</h2>
</div><p>In other news, Director Michael S. Perry sold 16,250 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a total value of $991,737.50. Following the completion of the sale, the director directly owned 115,240 shares in the company, valued at approximately $7,033,097.20. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Director Mauro Ferrari sold 8,750 shares of the firm's stock in a transaction on Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the completion of the transaction, the director owned 68,764 shares in the company, valued at $3,877,601.96. The trade was a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 45,000 shares of company stock valued at $2,185,150. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Michael S. Perry 於 12 月 5 日星期五出售了 16,250 股公司的股票。股票以平均價格 61.03 美元出售，總價值為 991,737.50 美元。出售完成後，該董事直接持有 115,240 股公司股票，價值約為 7,033,097.20 美元。此次交易使其持股減少了 12.36%。該出售在向證券交易委員會的文件中披露，可以通過此超鏈接訪問。此外，董事 Mauro Ferrari 於 11 月 28 日星期五出售了 8,750 股公司的股票。股票以平均價格 56.39 美元出售，總交易額為 493,412.50 美元。交易完成後，該董事持有 68,764 股公司股票，價值 3,877,601.96 美元。此次交易使其持股減少了 11.29%。該出售的披露信息可在 SEC 文件中找到。在過去的九十天裏，內部人士已出售價值 2,185,150 美元的 45,000 股公司股票。公司內部人士持有該公司 4.30% 的股份。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Arrowhead Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc. 在美國開發治療難治性疾病的藥物。該公司的產品管線包括 Plozasiran，目前正在進行 2b 期和一項 3 期臨牀試驗，以治療高甘油三酯血癥、混合性血脂異常和乳糜微粒血癥；Zodasiran 正在進行 2b 期臨牀試驗，以治療血脂異常和高甘油三酯血癥；ARO-PNPLA3 正在進行 1 期臨牀試驗，以治療非酒精性脂肪性肝炎患者；ARO-RAGE 正在進行 1/2a 期臨牀試驗，以治療炎症性肺部疾病；ARO-MUC5AC 正在進行 1/2a 期臨牀試驗，以治療粘液阻塞性肺病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>How to Profit From Value Investing</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Arrowhead Pharmaceuticals 更好</li>
<li>投資者必須瞭解的場外（OTC）股票信息</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了遊戲</li>
<li>每股收益計算器：如何計算 EPS</li>
<li>3 只金融股票在 10 年期國債收益率上升時值得購買</li>
<li>如何從價值投資中獲利</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Arrowhead Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Arrowhead Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Arrowhead Pharmaceuticals 並不在名單上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Arrowhead Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Marex Group plc 收購了箭頭製藥公司 36,469 股股票